

Understanding the impact of resistant bugs on deaths in England

Submission date 28/05/2024	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 02/06/2024	Overall study status Ongoing	<input checked="" type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 14/10/2025	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Antimicrobial resistance refers to when bacteria, viruses, fungi and parasites (bugs) no longer respond to antibiotic medicines. It is usually caused by prolonged and repeated exposure of bugs to antibiotics, in people, animals or the environment, which helps bugs eventually build defence mechanisms against them. These bugs can then spread via contact from person to person, causing resistant infections to people who have not had antibiotics before. For this reason, previously effective treatments stop working due to antimicrobial resistance worldwide. Research has shown that infections from antibiotic resistant bugs are more likely to lead to death, disability, and additional stay in hospital. It has also been estimated that, by 2050, 10 million deaths a year will be caused by antimicrobial resistance.

Despite the importance of antimicrobial resistance, which has been characterised as a global health emergency by the World Health Organisation, we have limited information about how many people die every year due to infections resistant to antibiotics. This is because of a variety of factors. For example, studies have shown that doctors are more likely to record chronic health problems like cancer in the death certificate as the primary cause of death, and the contribution of infection is often underestimated. Another problem is that in order to find antibiotic resistant bugs, cultures from the patient need to be taken, which is not always performed. This leads to underestimation of true numbers of antibiotic resistant infections. Yet, knowing exactly how many people die due to antimicrobial resistance is important, as it drives political and public awareness about the problem, highlighting the need for better treatments.

Very few previous studies have tried to estimate the true numbers of deaths due to antibiotic resistant infections. They have primarily used a technique called modelling to do so. Modelling uses math to estimate the numbers of deaths, based on how groups of patients with antibiotic sensitive and antibiotic resistant infections behave, as well as total numbers of infections. Because modelling doesn't look at individual patient cases though, it can lead to erroneous results and underestimation of the problem.

In this study, we will attempt for the first time to calculate the total number of deaths caused by antibiotic resistant infections in England in 2021, 2022 and 2023. We aim to do that by anonymously linking the cause of death of each patient as documented on the death certificate

with the bugs they were positive for in cultures and specimens up to 28 days before the date of death.

Who can participate?

Every patient who died in England in 2021, 2022 and 2023 will be included in the study but their data will be collected in a way that will not allow them to be identified. Participants who expressed their wish for their data not to be used for research purposes before they died will be excluded. We believe that with this approach we will get more accurate data on the total number of people in England, in whom antimicrobial resistance contributed to their death.

What does the study involve?

Retrospective analysis of patient records.

What are the possible benefits and risks of participating?

None

Where is the study run from?

University College London (UK)

When is the study starting and how long is it expected to run for?

March 2024 to June 2026

Who is funding the study?

UK Health Security Agency

Who is the main contact?

ioannis.baltas.20@ucl.ac.uk

l.grandjean@ucl.ac.uk

Contact information

Type(s)

Principal investigator

Contact name

Dr Louis Grandjean

ORCID ID

<https://orcid.org/0000-0002-1457-8327>

Contact details

UCL GOS Institute of Child Health, Infection, Immunity & Inflammation Department, 30 Guilford St

London

United Kingdom

WC1N 1EH

+44 7712336582

l.grandjean@ucl.ac.uk

Type(s)

Public, Scientific, Principal investigator

Contact name

Dr Ioannis Baltas

ORCID ID

<https://orcid.org/0000-0002-8008-4835>

Contact details

UCL GOS Institute of Child Health, Infection, Immunity & Inflammation Department, 30 Guilford St

London

United Kingdom

WC1N 1EH

+44 7543780069

ioannis.baltas.20@ucl.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil Known

Integrated Research Application System (IRAS)

340243

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

IRAS 340243, CPMS 61354

Study information

Scientific Title

Recording Antimicrobial Resistance during Death Certification in England

Acronym

AMR-DC

Study objectives

1. That it is possible to calculate AMR-associated deaths by linking death certification and patient-level microbiological data.
2. That AMR-associated mortality has been increasing in England during the study period.
3. That AMR was associated with a significant number of deaths (>2% of total deaths) in England in 2021-2023.
4. That a significant proportion of deaths (>10%) due to infection in England in 2021, 2022 and 2023 were AMR-associated.
5. That ESBLs were the AMR resistance mechanism with the highest number of AMR-associated deaths in England during the study period.
6. That most AMR-associated deaths (>90%) occur in hospital, disproportionately affect patients in Intensive Care and patients under Haematology and Oncology.

7. That patients recording AMR-associated deaths have longer hospital length of stays, are more likely to be admitted to Intensive Care and require more prolonged organ support.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 20/03/2024, North West - Haydock Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8032; haydock.rec@hra.nhs.uk), ref: 24/NW/0084

Study design

Retrospective observational cohort

Primary study design

Observational

Study type(s)

Other

Health condition(s) or problem(s) studied

Antimicrobial resistance effect on mortality

Interventions

This will be a retrospective observational cohort study. Eligible patients will be identified through the Civil Registrations of Death database provided by NHS England and will be linked to the HES database, also held by NHS England, to obtain additional clinical metadata. Pseudonymised cases will be subsequently linked to the SGSS database (AMR module) held by UKHSA in order to detect clinical samples with AMR pathogens of interest within 28 days of the patient's death. Anonymised results will be analysed using a standardized pathway to determine whether each death was AMR-associated. The rate and total number of deaths associated with AMR in this cohort, the most important pathogens, pathogen drug-combinations and resistance mechanisms will be described.

Intervention Type

Other

Primary outcome(s)

Measured using clinical databases:

The total number of patients with AMR-associated deaths in England in 2021-2023

Key secondary outcome(s)

Measured using clinical databases:

1. The percentage of AMR-associated deaths in 2021, 2022 and 2023, including the monthly trend of totals numbers.
2. The total number and percentage of AMR-associated deaths for each site of infection, AMR pathogen of interest, pathogen-drug combination, and resistance mechanism.
3. Underlying cause of death (UCODs) and Multiple cause of death (MCDs) groupings percentages for the entire study cohort.
4. The total number and percentage of UCOD and MCDs that were AMR-associated.
5. The total number and percentage of patients with AMR-associated deaths who die in hospital

versus in the community.

6. The percentage of AMR-associated deaths per medical specialty for patients who died in hospital.

7. The association between AMR and healthcare utilisation (mode of admission, duration of stay in hospital, ICU admission rates and duration of stay, life-support duration).

8. The total number and percentage of patients with AMR pathogens of interest in sterile sites within 28 days of death without infection being recorded in the pathway that led to death in the MCCD.

9. The total number of patients who had AMR documented in their death certificate (by using the ICD-10 codes U82-84).

Completion date

30/06/2026

Eligibility

Key inclusion criteria

All patients who had their death registered in England between 01/01/2021 and 31/12/2023 will be included in this study.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

All

Lower age limit

0 years

Upper age limit

150 years

Sex

All

Total final enrolment

1520000

Key exclusion criteria

Only patients who had expressed the wish for their data not to be used for research purposes under the National Data Opt-Out (DOO) will be excluded.

Date of first enrolment

01/07/2024

Date of final enrolment

31/03/2026

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

UCL Great Ormond Street Institute of Child Health

30 Guilford Street

London

United Kingdom

WC1N 1EH

Sponsor information

Organisation

University College London

ROR

<https://ror.org/02jx3x895>

Funder(s)

Funder type

Government

Funder Name

UK Health Security Agency

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored for 3 years and may be available upon request from Dr Louis Grandjean (l.grandjean@ucl.ac.uk)

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file	version 1.1	25/05/2024	29/05/2024	Yes	No
Protocol file	version 1.2	08/10/2024	30/10/2024	No	No
Statistical Analysis Plan	Section 5.8 of the protocol version 1.1	25/05/2024	10/06/2024	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes